Epcoritamab plus chemo for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of aggressive B-cell lymphoma (like diffuse large B-cell lymphoma or high-grade B-cell lymphoma with certain genetic features) that hasn't been treated with chemo before (one cycle is allowed).
- You are 18 or older and willing to give written consent.
- You have at least one tumor that can be measured on a scan (1.5 cm in a lymph node or 1 cm elsewhere).
- You are generally active (can take care of yourself, up to needing some help).
- Your heart, kidneys, liver, and blood counts meet specific safety levels (tested by your doctor).
- You agree to use effective birth control during the study and for a period after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This study tests whether adding epcoritamab, a new immunotherapy drug, to standard chemotherapy (R-CHOP) can help patients with aggressive B-cell lymphomas. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.